Otello Stampacchia is a life sciences investor who founded Omega Funds and focuses on venture capital in oncology, immunology. See contact routes.
Otello Stampacchia is a life sciences investor who founded Omega Funds and focuses on venture capital in oncology, immunology, rare diseases, and precision medicine across the U.S. and Western Europe [1][4]. He leads stage-agnostic investments, primarily backing early Series A and B rounds as well as more mature biotechs, with the firm’s eighth fund totaling $647 million to invest in drug startups [3][4][5]. Notable portfolio companies include Adagio, Ikena, Kronos Bio, and Prevail (an Eli Lilly venture), reflecting Omega’s thesis of supporting companies addressing severe unmet medical needs and creating new therapeutics [4][5].
Details on this investor come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist investors in Boston.
Investors like Otello Stampacchia · Full investor directory · Investor access · Company funding database